Abbott Laboratories (ABT) › Analysis

Abbott Laboratories (ABT) holds above 50‑day average, upside bias

Published November 18, 2026 · ABT chart, levels and live analysis

Abbott Laboratories closed at $104.09 on November 18, 2026, still above its 50‑day moving average of $103.85 and the 40‑week trend line. The daily price is running in step with the weekly uptrend, and the stock is still beating the S&P 500 over the past 50 days (+4.5%). The balance of evidence leans positive for the next two to six weeks, though medium conviction reflects a modest downside risk from a weekly close below $104.06.

Why it matters

The most recent market event was a sizable outflow from the health‑care ETF XLV, which shed about $519 million in the week to November 16. That outflow reflects a short‑term rotation away from the sector, but the ETF’s 5‑day decline of –3.43% is less than ABT’s –4.76%, indicating the stock underperformed its own sector. The outflow was not driven by any specific Abbott news, so the price reaction was largely a sector‑wide sell‑off rather than a company‑specific catalyst.

ABT’s own news flow has been limited to corporate governance items: an extension of change‑in‑control agreements for senior executives and a Form 8‑K filing on director changes. Neither event altered the fundamental outlook, and the market has already priced the extensions as neutral. Consequently, the recent price drop from the November 4 peak of $115.51 (‑9.9%) is driven more by broader health‑care rotation than by a shift in Abbott’s earnings outlook.

Analyst consensus remains a “Buy” with a mean target of $118.91, implying the current price is about 12.5% below the average target. The spread between the low ($100) and high ($130) targets underscores a wide valuation range, but the mean target still sits well above the breakout math’s first target of $110.61.

Both sides of the debate acknowledge Abbott’s dividend pedigree – a 53‑year streak of increases – and its strong long‑term cash generation, as highlighted in a Warren Buffett‑style story of a 75‑year hold turning $180 into $7 million. Bullish articles stress the defensive nature of the stock and its dividend safety, while bearish commentary focuses on a recent downgrade by Argus citing guidance cuts and reimbursement uncertainty. The downgrade’s impact is muted; the stock remains above the 50‑day average and the weekly trend stays intact.

What the evidence says

Long‑term, the thesis that ABT is in an uptrend remains intact. The price sits above both its 10‑week and 40‑week averages, the 50‑day moving average is holding at $103.85, and the 200‑day average at $101.50 provides a solid support base. The stock’s relative strength versus the S&P 500 (+4.5% over 50 days) continues to validate the longer‑term bias.

For the next two to six weeks, the balance of evidence leans positive. The assessment calls for a bullish stance with medium conviction, supported by two of four conviction points: the daily trend aligns with the weekly uptrend and the stock is leading the S&P 500 over 50 days. The third point – lagging the health‑care sector XLV – is a negative, but it does not outweigh the two positives, which is why conviction stays at medium rather than high.

The strongest case against the bullish reading is the recent 5‑day underperformance of –4.76% versus the sector’s –3.43% and the S&P’s –3.84%. If the weekly close slips below $104.06, the prior invalidation rule would shift the bias, but the price is still comfortably above that level.

Levels that matter

The structure holds above the 50‑day moving average at $103.85; a break below that would be the first crack in the uptrend. The trend would be considered ended if the price fell beneath the 200‑day average at $101.50, a level that also triggers a picture change on a weekly close below it.

The breakout math looks for a daily close above the swing‑zone resistance at $104.55 on volume exceeding the 20‑day average. If that occurs, the first target is $110.61, offering a reward‑to‑risk of roughly 4.1 based on the stop at $103.06 (derived from $103.85 minus a quarter of the 14‑day ATR of $3.17). The second target at $117.08 raises the reward‑to‑risk to about 8.4. The math meets a 3‑to‑1 risk‑reward ratio, so the upside case is statistically sound.

What would change the picture

A weekly close below the 200‑day average at $101.50 would alter the outlook, as it would signal the weekly trend has broken. Any significant sector‑wide news that reverses the XLV outflow, such as a major health‑care policy shift, could also reset the bias.

What to watch

Get a message when the ABT picture changes — the agent team watches the levels and the news for you.Create a free account

More ABT analyses

Research & education, not advice. MarketCrew is AI-powered and can make mistakes.